1 Six lactating white women, aged 24-36 years, received a single oral dose of 300 mg moclobemide, between 09.00 h and 11.00 h, 3 to 5 days after the delivery of a full term neonate. 2 Complete milk collections were obtained before, 3, 6, 9, 12 and 24 h after drug administration by means of a breast pump. Venous blood samples were drawn before, and 0.5, 1, 3, 4.5, 6, 9, 12, 24 h post-dosing. 3 Moclobemide, and its major metabolite (Ro 12-8095) were measured in milk and plasma samples using h.p.l.c. The active metabolite (Ro 12-5637) could only be detected in plasma. 4 Moclobemide and its metabolites were not detectable in 24 h plasma samples. Cmax, tmax and t½h for moclobemide were (mean ± s.d.) 2.70 ± 1.24 mg l-1, 2.03 ± 1.19 h and 2.26 ± 0.26 h, respectively. 5 The concentrations of moclobemide and Ro 12-8095 in milk were highest at 3 h after drug administration and the drug and metabolite were not detectable after 12 h. Ro 12-5637 was not detected in any milk sample. The percentages of the dose excreted as moclobemide and Ro 12-8095 were (mean ± s.d.) 0.057 ± 0.020% and 0.031 ± 0.011%, respectively. An average 3.5 kg breast-fed neonate would therefore be exposed to only a 0.05 mg kgmoclobemide dose (approximately 1% of the maternal dose on the mg kg-' basis).
Introduction
Moclobemide, a benzamide derivative, is a new management of postnatal depression. The adreversible monoamine oxidase-A inhibitor vantages of breast feeding in this condition are (Keller et al., 1987) . It possesses an anti-well recognized and physicians are often redepressant efficacy comparable with that of luctant to advise discontinuation of breast feedclomipramine, amitriptyline and imipramine ing because of potential risks to the infant posed (Larsen et al., 1984; Norman et al., 1985;  Stabl by the presence of an antidepressant drug in et al., 1989) and superior to that of placebo mother's milk. The purpose of this study was to (Casacchia et al., 1984; Stabl et al., 1989) . Most measure the time course of moclobemide and its patients tolerate moclobemide better than tri-metabolites in human milk and to determine the cyclic antidepressants (Larsen et al., 1984 ; Stabl exposure of breast-fed neonates after a single et al., 1989 Moclobemide is a weak base (pKa 6.3) with an n-octanol/water distribution coefficient of 62 at a pH of 7.4 and a molecular weight of 269. It is 50% bound to plasma proteins (Schoerlin et al., 1989) . Data (Schoerlin et al., 1987) .
Ro 12-8095, the main metabolite, produced by hydroxylation of the morpholine ring, is inactive while Ro 12-5637 produced by Noxidation of the same ring is active.
Methods
Six lactating white women, ranging in age from 24 to 36 years, in height from 158 to 172 cm and in weight from 48 to 63 kg were recruited to the study. Each subject was in good health as assessed by medical history, physical examination and routine laboratory tests. The study was performed on day 3 to 5 after delivery of a full term neonate. Mothers nursing twins were excluded. The subjects had not used any medication known to induce or inhibit drug metabolism, for at least 2 weeks before drug administration and during the study. Written informed consent was obtained from all subjects prior to the study. The protocol was approved by the UER Cochin PortRoyal Ethics Committee. Before the study each mother agreed to stop nursing her infant for 24 h after drug administration.
Each mother received a single oral dose of 300 mg moclobemide as three 100 mg tablets with 120 ml of water between 09.00 h and 11.00 h after a low-fat breakfast. A lunch was served 4 h after drug intake. During the entire blood sampling period, the subjects were allowed light meals which were low in fat. Breast milk was collected using an Egnell SMB breast electric pump (AMEDA AG, Zug, Switzerland). The working cycle of the breast pump is divided into three phases: a short suction phase, during which the pressure decreases from atmospheric pressure to 520 mm Hg (negative pressure of 240 mm Hg); a short relief phase, back to atmosphere pressure; a resting phase under slight overpressure of about 10 mm Hg. The suction rhythm is of 48 periods min-'. Milk samples were collected immediately before dosing and 3, 6, 9, 12, 24 h after drug administration. Available milk was collected as completely as possible from each breast. Blood samples were drawn, immediately before, 0.5, 1, 3, 4.5, 6 and 9 h after drug administration in the first two patients. Two additional blood samples were taken, 12 and 24 h post-dosing in the remaining four. Plasma and milk samples were stored at -20°C until analysis.
The concentrations of moclobemide and its metabolites (Ro 12-5637) and (Ro 12-8095) in plasma were measured by h.p.l.c. (Geschke et al. 1987 (Lam et al., 1985) .
Results
Milk yield was 440 ± 103 ml 24 h-l and 82.6 + 37.5 ml/time-point. Mean plasma moclobemide and metabolite plasma concentration-time curves are shown in Figure la 
Discussion
The experimental design took into consideration the significant changes, previously described (Wilson et al., 1980) , in milk composition and yield, which depend on the time of sampling during a feeding, the side of collection, the time of the day, the stage of lactation and the nutritional state. The sampling protocol was standardized to allow interpatient compansons and also for the measurement to be relevant to clinical practice. Milk was sampled from each breast as completely as possible in order to obtain samples representative of a complete feed. The time interval between consecutive milk collections was similar to that of a regular schedule of breast feeding. In all patients the study was performed during the fourth to the sixth days postpartum and at the same time of the day. All of the lactating mothers were well nourished and had given birth to a full term neonate. Drug excretion in breast milk is primarily by passive diffusion across the mammary membranes leading to rapid equilibration of drug between plasma and milk (Wilson et al., 1980) . Breast milk can, therefore, be considered as a compartment with bidirectional transfer across a blood-milk barrier rather than a bladder with milk accumulation between two consecutive collections. We thus chose to consider each milk sample as instantaneous, at the mid-point of the milk collection interval, rather than to consider the amount of drug recovered as the result of drug accumulation in breast during the time elapsed since the previous milk collection. The parallel decline of milk and plasma moclobemide concentrations (Figure la and lb) support the hypothesis of rapid equilibration of drug between plasma and milk. The kinetic parameters describing the time course of moclobemide in plasma in the lactating mothers following a 300 mg dose are consistent with those observed in previous studies in healthy male volunteers (Data on file Hoffmann La Roche).
We have shown that breast-fed neonates from mothers treated with a single 300 mg oral dose of moclobemide would be exposed to only a small amount of the drug and its major and inactive metabolite Ro 12-8095 when fed as early as 3 h after drug administration. Using the total amounts of compounds recovered in breast milk over the period of the study, a child weighing 3.5 kg is estimated to receive, on average, about 0.050 mg kg-l moclobemide (approximately 1% of the maternal dose on the mg kg-1 basis) and 0.028 mg kg'-Ro 12-8095, assuming that such a 3-5 day old infant would be able to ingest the relatively large amount of milk collected. The amount of moclobemide transferred into milk is not expected to be very much higher after the 6th day post-delivery due to changes in milk yield and composition which occur during maturation.
During multiple dosing, accumulation of the compounds in plasma and breast milk may occur. Accumulation in plasma has been demonstrated in healthy volunteers. Furthermore, moclobemide exhibits non linear kinetics when given as a 100 mg dose three times daily for 15 days, the steady-state area under the plasma drug concentration-time curve being two times higher than after a single 100 mg dose (Schoerlin et al., 1987) . The dosage used in the present study is two to three times higher than a single therapeutic dose. Thus, the AUC obtained in the present study in lactating mothers receiving a single 300 mg dose was similar to that, at steadystate, in healthy volunteers receiving 150 mg three times daily (Data on file Hoffmann La Roche). The dosage used in the present study might, therefore, be considered as representative of steady-state conditions, suggesting that exposure of breast-fed neonates during a dosing interval of a 150 mg three times daily therapeutic chronic dose is not expected to be different to that following a single 300 mg dose. The low amount of moclobemide excreted into breast milk is unlikely to be hazardous to suckling infants.
